1 Min Read
March 31 (Reuters) - Forward Pharma A/S
* US Patent Trial and Appeal Board ruling is about “interference” and follows earlier ruling for biogen on ipr Further company coverage: (Reporting By Caroline Humer)
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.